Rosiglitazone Use and the Risk of Bladder Cancer in Patients with Type 2 Diabetes

Medicine (United States)

Volumn 95, Issue 6, 2016, Pages

  Han, Eugene ^a,b   Jang, Suk Yong ^d   Kim, Gyuri ^a,b   Lee, Yong Ho ^a,c   Choe, Eun Yeong ^b,e   Nam, Chung Mo ^d   Kang, Eun Seok ^a,b,c  

^a Sungkyunkwan University   (South Korea)

^b Graduate School   (South Korea)

^c Institute of Endocrine Research   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e International St Mary's Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE; ANTIDIABETIC AGENT;

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DRUG INDUCED CANCER; DRUG USE; FEMALE; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; INCIDENCE; MIDDLE AGED; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; RISK ASSESSMENT; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84958292047     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002786     Document Type: Article

References (36)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40.
2. American Diabetes Association. (7) Approaches to glycemic treatment. Diabetes care. 2015;38:S41-S48.
3. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 2002;18:S10-S15.
4. Picard F, Auwerx J. PPAR (gamma) and glucose homeostasis. Annu Rev Nutr. 2002;22:167-197.
5. Hevener AL, Olefsky JM, Reichart D, et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest. 2007;117:1658-1669.
6. Larsson SC, Orsini N, Brismar K, et al. Diabetes mellitus and risk of bladder cancer: A meta-Analysis. Diabetologia. 2006;49:2819-2823.
7. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested casecontrol study. Br Med J. 2012;344:e3645.
8. Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Reply to Perez AT [letter]. Diabetologia. 2013;56:228-229.
9. Ryder RE. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabet Med. 2015;32:305-313.
10. Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: A multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58:493-504.
11. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, et al. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: An overview of data from PROactive. Drug Saf. 2009;32:187-202.
12. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet. 2005;366:1279-1289.
13. Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. J Am Med Assoc. 2015;314:265-277.
14. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916-922.
15. Monami M, Dicembrini I, Mannucci E. Thiazolidinediones and cancer: results of a meta-Analysis of randomized clinical trials. Acta Diabetol. 2014;51:91-101.
16. Ahn YS, Jeong KS. Mortality due to malignant and non-malignant diseases in Korean professional emergency responders. PLoS One. 2015;10:e0120305.
17. Rothman KJ, Lash TL, Greenland S. Modern Epidemiology. 3 ed. Philadelphia: Lippincott, Williams & Wilkins; 2008.
18. International Statistical Calssification and Diseases and Related Health Problmes. Vol 2. 10th revision ed. Geneva, Switzerland: World Health Organization; 2010
19. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
20. Song SO, Kim KJ, Lee BW, et al. The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. Diabetes Metab J. 2012;36:371-378.
21. Song W, Jeon HG. Incidence of kidney, bladder, and prostate cancers in Korea: An update. Korean J Urol. 2015;56:422-428.
22. Tseng CH. Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan. Diabetologia. 2011;54:2009-2015.
23. Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: A cohort study. J Natl Cancer Inst. 2012;104:1411-1421.
24. Dominick MA, White MR, Sanderson TP, et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol. 2006;34:903-920.
25. Lubet RA, Fischer SM, Steele VE, et al. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl (butyl)nitrosamineinduced urinary bladder cancers. Int J Cancer. 2008;123:2254-2259.
26. Hsiao FY, Hsieh PH, Huang WF, et al. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: A nested case-control study. Drug Saf. 2013;36:643-649.
27. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30:2458-2464.
28. Devchand PR, Keller H, Peters JM, et al. The PPAR alphaleukotriene B4 pathway to inflammation control. Nature. 1996;384:39-43.
29. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-Activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995;15:3012-3022.
30. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators. Nature. 1998;393:790-793.
31. Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
32. Tontonoz P, Nagy L, Alvarez JG, et al. PPAR gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
33. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547-1554.
34. Fauconnet S, Lascombe I, Chabannes E, et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-Activated receptors in bladder cancer cells. J Biol Chem. 2002;277:23534-23543.
35. Inoue M, Itoh H, Tanaka T, et al. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferatoractivated receptor-gamma. Arterioscler Thromb Vasc Biol. 2001;21:560-566.
36. Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. J Am Med Assoc. 2011;306:737-745.